UBS raised the firm’s price target on Zimmer Biomet (ZBH) to $89 from $86 and keeps a Sell rating on the shares. Execution remains a key area to monitor following the Q4 earnings report, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target raised to $98 from $94 at Citi
- Zimmer Biomet Earnings Call Balances Growth and Risk
- Morning Movers: Fiserv and Spotify jump following fourth quarter results
- Zimmer Biomet reports Q4 adjusted EPS $2.42, consensus $2.40
- Zimmer Biomet board approves $1.5B stock repurchase program